Navigation Links
Lorus Therapeutics Announces Scientific Presentations for Lead,Antisense and siRNA Drug Candidates at International Cancer,Conference

strategies involving antisense and siRNA," commented Dr. Aiping Young, Lorus' President and CEO. "The novel findings involving GTI-2040 combined with docetaxel provide an important new approach for optimizing combination therapies with GTI-2040, which may be particularly relevant to future GTI-2040 trials in solid tumor indications. We are also very pleased with the identification of our lead siRNA drug, adding to our growing platform of DNA/RNA-based medicines."

About GTI-2040

GTI-2040 is an antisense drug that specifically targets the R2 component of ribonucleotide reductase, which is required for DNA synthesis and cell proliferation. R2 has also been described as a malignant determinant that is elevated in a wide range of tumors, and through down regulation can cooperate with a variety of cellular cancer causing genes known as oncogenes to enhance tumor growth and metastatic potential.

About siRNA

siRNA is a novel class of molecules that can decrease cellular target RNA expression through an antisense process known as RNA interference (RNAi). Because of its target specificity, RNAi is increasingly being examined as a potential therapy for a variety of diseases including cancer. From an evolutionary perspective, RNAi helps protect cells from viruses and transposable genetic elements in addition to carrying out more routine cellular tasks essential to development and growth. In mammalian cells siRNAs have been shown to be the most effective tools for RNAi, allowing for the development of clean and easily regulated methods for disruption of gene expression. siRNA technology allows for a range of new applications including target validation for drug discovery and medical therapeutics.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of novel therapeutics in cancer. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candida
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:8/29/2014)... , Aug. 29, 2014 Medina Medical announced ... and member of the Board of Directors on August ... device development and commercialization experience, including over a decade ... previously served as a Partner of the medical device ... CEO of two Foundry start-ups. Mr. Engelson previously served ...
(Date:8/29/2014)... Research and Markets  has announced the addition of the ... to their offering. The Central Nervous System ... segments of pharmaceuticals industry. The numbers of CNS disorders have ... unable to meet the market requirements. There has been steady ... over the past two decades. The market for CNS therapies ...
(Date:8/29/2014)... Corporation , a neurodiagnostics medical device company based in ... Forcht Dagi , MD, DmedSc, MPH, MBA, FACS, FRCSEd  was ... " Teo Forcht Dagi is an experienced leader with ... said Remis Bistras , President and CEO of Vittamed. ... entrepreneurial expertise to our Board." Dr. Dagi is ...
Breaking Medicine Technology:Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2US CNS Disorders Drug Pipeline Insight 2014 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2
... Data Reviewed in End of Phase 2a Meeting , ... (Nasdaq: VIAP ), a biotechnology company focused on ... metabolic disease, announced today that an end of Phase 2a ... held with the U.S. Food and Drug Administration (FDA). ...
... New Capabilities Will Further Extend GeneXpert System Technology Advantages , ... CPHD ) today announced that it has received a ... and Infectious Diseases to develop new ten-color detection technology for ... be awarded to Cepheid and the University of Medicine ...
Cached Medicine Technology:VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 2VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 3VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 5Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System 2Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System 3Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System 4
(Date:8/31/2014)... Aliso Viejo, California (PRWEB) August 31, 2014 ... release of ProPixie 5K. This plugin is a composite footage ... Cut Pro X. , “Adding particle footage to a video ... Christina Austin, CEO of Pixel Film Studios. “ProPixie 5K gives ... Editors can give their film an epic or magical ...
(Date:8/31/2014)... (PRWEB) August 31, 2014 With the ... Conflict Institute hosted an interview with Yale University ... as well as Yale’s approach to ensuring student-athlete experience ... the interview, Conn highlighted a number of key factors ... university. A critical factor in creating this culture ...
(Date:8/31/2014)... 31 August 2014: Mortality and morbidity of atrial ... good use of oral anticoagulants, according to the one ... Registry. The findings were presented for the first time ... Gregory Lip (Birmingham, UK). , Professor Lip said: "This ... management practices of European cardiologists conducted since the ESC ...
(Date:8/30/2014)... Florida (PRWEB) August 31, 2014 Walking-Canes.Net ... walking and how a mobility device can help in making ... available for free download from the website that contains all ... doctor for this site. , The articles deal with diseases ... device like a walking cane can help in making life ...
(Date:8/30/2014)... August 31, 2014 This Labor Day, ... growing union in New York State and nationwide, is ... jobs and the best quality of care to New ... recent years, thousands of healthcare workers in the region ... families by becoming members of the healthcare workers’ union. ...
Breaking Medicine News(10 mins):Health News:Announcing a New ProPixie 5K Composite Footage Pack from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Yale University’s Steve Conn Discusses NCAA Football, Student-Athlete Experience, & Social Media SCI Talk Interview 2Health News:Yale University’s Steve Conn Discusses NCAA Football, Student-Athlete Experience, & Social Media SCI Talk Interview 3Health News:AF mortality and morbidity high at 1 year despite good anticoagulant use 2Health News:Information Articles on Gait Problems from Walking-Canes.Net 2Health News:This Labor Day, 1199SEIU Continues Commitment to Growing Local Economies with Good, Middle-Class Healthcare Jobs 2Health News:This Labor Day, 1199SEIU Continues Commitment to Growing Local Economies with Good, Middle-Class Healthcare Jobs 3Health News:This Labor Day, 1199SEIU Continues Commitment to Growing Local Economies with Good, Middle-Class Healthcare Jobs 4
... ... ... , ... , , ...
... ... use of mobile technology and their participation in online physician networking. Approximately 30% ... popular handheld device or smartphone is the Apple iPhone, with 31% of respondents owning ... Plymouth ...
... trouble by mid-40s, despite activity levels, study finds , WEDNESDAY, March ... 20s and 30s are more apt to develop heart disease risk ... spent less time in front of the screen, a new study ... news is that you can,t exercise the risk away. , The ...
... ... ... , , , ... ...
... ... ... ... ...
... , ... ... ... ...
Cached Medicine News:Health News:Statement from Larry Minnix, President & CEO, American Association of Homes and Services for the Aging, On the Therapy Cap Coalition Press Conference 2Health News:SDI Reports: Nearly a Third Of Physicians Use Handheld and Smartphone Devices to Access Medical Information - Physicians Most Likely to be Using Apple iPhone 2Health News:SDI Reports: Nearly a Third Of Physicians Use Handheld and Smartphone Devices to Access Medical Information - Physicians Most Likely to be Using Apple iPhone 3Health News:You Can't Exercise Away TV's Toll on the Heart 2Health News:You Can't Exercise Away TV's Toll on the Heart 3Health News:March of Dimes President Dr. Jennifer L. Howse Wins Prestigious Humanitarian Award 2Health News:March of Dimes President Dr. Jennifer L. Howse Wins Prestigious Humanitarian Award 3Health News:March of Dimes President Dr. Jennifer L. Howse Wins Prestigious Humanitarian Award 4Health News:Kaiser Permanente Completes Electronic Health Record Implementation 2Health News:Kaiser Permanente Completes Electronic Health Record Implementation 3Health News:Kaiser Permanente Completes Electronic Health Record Implementation 4Health News:Kaiser Permanente Completes Electronic Health Record Implementation 5Health News:Kaiser Permanente Completes Electronic Health Record Implementation 6Health News:Seattle Sutton's Healthy Eating Sponsoring The Biggest Loser Chicago Casting Call 2Health News:Seattle Sutton's Healthy Eating Sponsoring The Biggest Loser Chicago Casting Call 3Health News:Seattle Sutton's Healthy Eating Sponsoring The Biggest Loser Chicago Casting Call 4
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Infusion Cannula, 6.0mm....
Subretinal Aspiration Cannula, Curved; 20g (0.90) x 1" (25mm); Tip Extension: 6.5mm, 27g (0.40); Angled at 60°, 2.5mm from Tip....
Subretinal Fluid Cannula, Straight; 20g (0.90) x 1-1/2" (38mm); 12mm Flexible Tubing Extends 6mm Beyond Tip....
Medicine Products: